{"id":"peginterferon-2b","safety":{"commonSideEffects":[{"rate":"50-70%","effect":"Flu-like symptoms"},{"rate":"30-50%","effect":"Fatigue"},{"rate":"20-40%","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL1201560","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It does this by inducing the production of antiviral proteins and activating immune cells to target and eliminate infected cells. Peginterferon α2b is a pegylated form of interferon α2b, which allows for a longer duration of action and reduced dosing frequency.","oneSentence":"Peginterferon α2b works by stimulating the body's immune system to fight viral infections.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:47:37.752Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C"},{"name":"Chronic hepatitis B"}]},"trialDetails":[{"nctId":"NCT02737046","phase":"PHASE2","title":"Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma","status":"COMPLETED","sponsor":"University of Miami","startDate":"2016-12-12","conditions":"Adult T-cell Leukemia-Lymphoma, ATLL","enrollment":15},{"nctId":"NCT07438093","phase":"NA","title":"Safety, Tolerability, and Preliminary Efficacy of Peginterferon α-2b in Combination With an Anti-PD-1 Antibody in Patients With Advanced or Metastatic Malignant Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2026-04","conditions":"Advanced Solid Tumors","enrollment":60},{"nctId":"NCT06552429","phase":"PHASE2","title":"Peginterferon α-2b Injection for Hydroxyurea Resistant or Intolerant ET","status":"RECRUITING","sponsor":"Xiamen Amoytop Biotech Co., Ltd.","startDate":"2024-08-29","conditions":"Essential Thrombocythemia","enrollment":27},{"nctId":"NCT07231276","phase":"PHASE4","title":"Prospective Cohort Study on PEG-IFN-α-2b in Improving Clinical Cure Rate of Pediatric Patients With Chronic Hepatitis B","status":"NOT_YET_RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2026-01-01","conditions":"HBV, Chronic Hepatitis B Virus","enrollment":113},{"nctId":"NCT07183293","phase":"NA","title":"A Study on Peginterferon Alfa-2b Combined With NAs in Compensated HBV Cirrhosis","status":"NOT_YET_RECRUITING","sponsor":"Xiamen Humanity Hospital","startDate":"2025-10","conditions":"HBV-related Liver Cirrhosis","enrollment":30},{"nctId":"NCT07169656","phase":"","title":"Observation Study on Reducing the Risk of Liver Cancer Associated With Hepatitis B (Zhiyuan) Project.","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2024-06-03","conditions":"Chronic Hepatitis b","enrollment":15000},{"nctId":"NCT07008755","phase":"NA","title":"Clinical Trial of Pegylated Interferon α-2b Via Nebulization for Treatment of Hand, Foot, and Mouth Disease .","status":"RECRUITING","sponsor":"Zhengzhou Children's Hospital, China","startDate":"2024-07-31","conditions":"HFMD","enrollment":90},{"nctId":"NCT05182463","phase":"PHASE4","title":"Peginterferon Treatment Study for Inactive Chronic Hepatitis B Patients","status":"RECRUITING","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2022-01-08","conditions":"Hepatitis B, Chronic","enrollment":5000},{"nctId":"NCT06920329","phase":"NA","title":"Effects of Peginterferon Consolidation Therapy on Hepatic cccDNA Dynamics in CHB Patients Achieving Clinical Cure.","status":"NOT_YET_RECRUITING","sponsor":"Xiamen Hospital of Traditional Chinese Medicine","startDate":"2025-04-20","conditions":"Chronic Hepatitis b","enrollment":30},{"nctId":"NCT06881056","phase":"NA","title":"Peginterferon α-2b Injection for Aerosol Therapy in Pediatric Respiratory Syncytial Virus Pneumonia","status":"RECRUITING","sponsor":"West China Second University Hospital","startDate":"2024-07-17","conditions":"Respiratory Syncytial Virus (RSV)","enrollment":90},{"nctId":"NCT06827249","phase":"NA","title":"Peginterferon α-2b Injection for the Treatment of Pediatric RSV Bronchiolitis","status":"RECRUITING","sponsor":"Children's Hospital of Soochow University","startDate":"2025-03","conditions":"Bronchiolitis","enrollment":90},{"nctId":"NCT06746701","phase":"","title":"Study on the Treatment of Hepatitis B Virus(HBV) Infected Individuals With Peginterferon α-2b Combined With NA.","status":"RECRUITING","sponsor":"Xiangya Hospital of Central South University","startDate":"2023-05-25","conditions":"HBV","enrollment":400},{"nctId":"NCT06734637","phase":"NA","title":"Efficacy and Safety of Peginterferon in ET and PV.","status":"RECRUITING","sponsor":"Zhenya Hong","startDate":"2024-11-20","conditions":"Essential Thrombocythemia, Polycythemia Vera","enrollment":40},{"nctId":"NCT06707922","phase":"NA","title":"A Follow-up Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B","status":"ENROLLING_BY_INVITATION","sponsor":"Xiamen Amoytop Biotech Co., Ltd.","startDate":"2022-03-18","conditions":"Chronic Hepatitis B","enrollment":350},{"nctId":"NCT06430190","phase":"NA","title":"Peginterferon α-2b Combined CO2 Laser in Condylomata Acuminata","status":"NOT_YET_RECRUITING","sponsor":"Zhangyu Bu","startDate":"2024-07","conditions":"Condylomata Acuminata","enrollment":30},{"nctId":"NCT06323681","phase":"NA","title":"Pegylated Interferon α in Previously Interferon-treated CHB（Leading Study）","status":"RECRUITING","sponsor":"Qing XIe","startDate":"2024-02-04","conditions":"Chronic Hepatitis b","enrollment":2016},{"nctId":"NCT05988879","phase":"","title":"Functional Cure of Hepatitis B in HIV/HBV Co-infected Patients","status":"RECRUITING","sponsor":"Guangzhou 8th People's Hospital","startDate":"2023-08-02","conditions":"AIDS, Hepatitis B","enrollment":60},{"nctId":"NCT01657604","phase":"PHASE3","title":"TKI and Interferon Alpha Evaluation Initiated by the German Chronic Myeloid Leukemia Study Group - the TIGER Study","status":"COMPLETED","sponsor":"University of Jena","startDate":"2012-08-24","conditions":"Chronic Myeloid Leukemia","enrollment":717},{"nctId":"NCT02634294","phase":"PHASE2, PHASE3","title":"Peg Interferon α-2b for Relapsed Hematological Malignancies After Allo-HSCT","status":"COMPLETED","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2015-08","conditions":"Hematological Neoplasms, Recurrence","enrollment":30},{"nctId":"NCT00573378","phase":"PHASE2","title":"Imatinib or Nilotinib With Pegylated Interferon-α2b in Chronic Myeloid Leukemia","status":"TERMINATED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2007-09","conditions":"Chronic Myeloid Leukemia","enrollment":12},{"nctId":"NCT05490836","phase":"NA","title":"Functional Cure Rate of Peg-IFNα-2b Combined With TAF in HBeAg Negative CHB Patients","status":"UNKNOWN","sponsor":"Huashan Hospital","startDate":"2022-09","conditions":"Chronic Hepatitis B","enrollment":200},{"nctId":"NCT05451420","phase":"NA","title":"Inactive HBsAg Carriers (IHCs) Treated With Pegylated Interferon α2b Based Intervention Therapy","status":"COMPLETED","sponsor":"Henan Provincial People's Hospital","startDate":"2017-12-01","conditions":"Chronic Hepatitis B","enrollment":33},{"nctId":"NCT03588715","phase":"PHASE1","title":"Peg-Interferon Alpha 2b Combined With Two Intravenous Broadly HIV-1 Neutralizing Antibodies 3BNC117 and 10-1074 (BEAT-2)","status":"UNKNOWN","sponsor":"Luis Montaner","startDate":"2020-06-18","conditions":"HIV, HIV/AIDS, HIV-1 Infection","enrollment":15},{"nctId":"NCT01872442","phase":"PHASE2","title":"Combination of Dasatinib and Peg-Interferon Alpha 2b in First Line for Chronic Myeloid Leukemia in Chronic Phase","status":"COMPLETED","sponsor":"Poitiers University Hospital","startDate":"2013-10-15","conditions":"Chronic Phase of Chronic Myeloid Leukemia","enrollment":""},{"nctId":"NCT00724061","phase":"NA","title":"Study of Pegylated Interferon-Alfa 2b in Combination With PUVA Therapy In CTCL","status":"TERMINATED","sponsor":"Northwestern University","startDate":"2008-09","conditions":"Lymphoma","enrollment":7},{"nctId":"NCT01866553","phase":"PHASE2","title":"Nilotinib Plus Pegylated Interferon-α2b in CML","status":"TERMINATED","sponsor":"Amsterdam UMC, location VUmc","startDate":"2013-04","conditions":"Chronic Myeloid Leukemia","enrollment":20},{"nctId":"NCT02227277","phase":"PHASE2","title":"Reducing Proviral HIV DNA With Interferon-a","status":"UNKNOWN","sponsor":"The Wistar Institute","startDate":"2015-02-11","conditions":"HIV, HIV/AIDS","enrollment":54},{"nctId":"NCT00759109","phase":"PHASE3","title":"Pegylated Alfa-2b Interferon Therapy of Patients With Hepatitis C-related Cirrhosis and High Liver Cell Proliferation (P02733/MK-4031-085)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2002-03","conditions":"Carcinoma, Hepatocellular","enrollment":150},{"nctId":"NCT00732641","phase":"PHASE3","title":"Peginterferon α-2b as a Maintenance Therapy in Participants With Multiple Myeloma Who Responded to Induction Therapy (P01972-AM7)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2000-12","conditions":"Multiple Myeloma","enrollment":244},{"nctId":"NCT00585221","phase":"PHASE2","title":"Study of Imatinib and Peginterferon α-2b in Gastrointestinal Stromal Tumor (GIST) Patients","status":"TERMINATED","sponsor":"University of Utah","startDate":"2007-07","conditions":"Gastrointestinal Stromal Tumors, Cancer Brain, Solid Tumors","enrollment":8},{"nctId":"NCT01463956","phase":"PHASE2","title":"Efficacy of PegInterferon-Ribavirin-Boceprevir Therapy in Patients Infected With G1 HCV With Cirrhosis, Awaiting Liver Transplantation","status":"COMPLETED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2012-01-06","conditions":"HCV Infection, Liver Cirrhosis, Experimental","enrollment":58},{"nctId":"NCT00548847","phase":"PHASE2","title":"Immunotherapy for Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Blast Phase Chronic Myelogenous Leukemia (BP CML), and Myelodysplastic Syndrome (MDS) Relapse After Allogeneic Transplantation","status":"COMPLETED","sponsor":"Emory University","startDate":"2007-01","conditions":"Leukemia","enrollment":15},{"nctId":"NCT00723632","phase":"","title":"Pharmacoeconomic Study Assessing the Cost of Chronic Hepatitis C Treatment With Peginterferon Alfa-2b (PegIntron) and Ribavirin (Rebetol) in the Czech Republic (Study P04588)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-09","conditions":"Hepatitis C, Chronic, Hepatitis C","enrollment":901},{"nctId":"NCT01585584","phase":"PHASE3","title":"Triple-Therapy in Patients With HCV Genotype 3 Who Previously Failed Treatment","status":"COMPLETED","sponsor":"University of Calgary","startDate":"2012-05","conditions":"Hepatitis C","enrollment":11},{"nctId":"NCT01290679","phase":"PHASE3","title":"An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Participants","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2011-03","conditions":"Hepatitis C","enrollment":393},{"nctId":"NCT01949168","phase":"PHASE2","title":"A Pilot Study of Boceprevir for the Treatment of Genotype 6 HCV","status":"UNKNOWN","sponsor":"St Vincent's Hospital Melbourne","startDate":"2013-09","conditions":"Chronic Hepatitis C","enrollment":30},{"nctId":"NCT01457937","phase":"PHASE3","title":"Boceprevir/PegIFN α-2b/Riba in HCV+ Gt1 Menopausal Women, Nonresponders to PegIFN/Riba or Treatment-naives (MEN_BOC)","status":"UNKNOWN","sponsor":"University of Modena and Reggio Emilia","startDate":"2011-11","conditions":"Chronic Hepatitis C, Menopause","enrollment":240},{"nctId":"NCT01683786","phase":"PHASE4","title":"36 vs 48 Wks Peg-Intron Plus Ribavirin for HCV Patients Without Rapid Virologic Response But Without HCV RNA at wk 8","status":"UNKNOWN","sponsor":"Chang Gung Memorial Hospital","startDate":"2011-08","conditions":"Hepatitis C Infection","enrollment":60},{"nctId":"NCT00623402","phase":"PHASE2","title":"Combined Treatment of Sorafenib and Pegylated Interferon α2b in Stage IV Metastatic Melanoma","status":"COMPLETED","sponsor":"University Hospital Schleswig-Holstein","startDate":"2008-01","conditions":"Melanoma","enrollment":55}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":30,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Redipen"],"phase":"phase_3","status":"active","brandName":"Peginterferon α2b","genericName":"Peginterferon α2b","companyName":"University of Jena","companyId":"university-of-jena","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Peginterferon α2b works by stimulating the body's immune system to fight viral infections. Used for Chronic hepatitis C, Chronic hepatitis B.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}